Also found in: Acronyms, Wikipedia.



Pharmacologic class: Alkylator

Therapeutic class: Antineoplastic

Pregnancy risk category D

FDA Box Warning

• Anaphylaxis may occur within minutes of administration. Epinephrine, corticosteroids, and antihistamines have been used to relieve symptoms.


Unclear. Thought to form reactive platinum complexes that inhibit DNA synthesis through formation of interstrand and intrastrand cross-linking of DNA molecules. Cell-cycle-phase nonspecific.


Powder for reconstitution for injection, lyophilized: 5 mg/ml in 50-mg and 100-mg single-use vials

Solution for injection: 5 mg/ml in 10-ml, 20-ml, and 40-ml single-use vials

Indications and dosages

Metastatic cancer of colon or rectum, given with 5-fluorouracil (5-FU) and leucovorin

Adults: On day 1, 85 mg/m2 oxaliplatin I.V. infusion and 200 mg/m2 leucovorin; give both drugs simultaneously over 2 hours, followed by 400 mg/m2 I.V. bolus of 5-FU over 2 to 4 minutes, then 600 mg/m2 5-FU I.V. as 22-hour continuous infusion. On day two, 200 mg/m2 leucovorin I.V. infusion over 2 hours, followed by 400 mg/m2 5-FU I.V. bolus over 2 to 4 minutes, then 600 mg/m2 5-FU I.V. as 22-hour continuous infusion.


• Hypersensitivity to drug or platinum products


Use cautiously in:

• thrombocytopenia

• radiation therapy

• recent pneumococcal or smallpox vaccination

• elderly patients

• pregnant or breastfeeding patients

• children.


Follow facility policy for preparing, handling, and administering mutagenic, teratogenic, and carcinogenic drugs.

• Premedicate patient with antiemet-ics, as prescribed.

• Reconstitute with sterile water or dextrose 5% in water (D5W)-never with normal saline solution or other solutions containing chloride.

• Further dilute reconstituted drug in 250 to 500 ml of D5W.

• Infuse over 2 hours simultaneously with leucovorin, but in a separate I.V. bag.

• Don't use administration sets or needles that contain aluminum.

Be aware of importance of using leucovorin rescue with this drug.

Avoid extravasation, which may cause necrosis and other severe reactions.

• Know that treatment cycles are usually repeated every 2 weeks.

Adverse reactions

CNS: headache, dizziness, fatigue, insomnia, peripheral neuropathy

CV: cardiac abnormalities

EENT: decreased visual acuity, hearing loss, tinnitus, rhinitis, pharyngitis

GI: severe nausea, vomiting, diarrhea, constipation, dyspepsia, gastroesoph-ageal reflux, mucositis, flatulence, stomatitis, anorexia

GU: hematuria, dysuria

Hematologic: anemia, thrombocytopenia, leukopenia, pancytopenia, neutropenia, hemolytic uremic syndrome

Metabolic: hypokalemia

Respiratory: dyspnea, cough, upper respiratory infection, pulmonary fibrosis

Skin: alopecia, rash, flushing, extravasation, redness, swelling, angioedema

Other: weight loss, increased cold sensitivity, pain at injection site, anaphylaxis


Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity

Aspirin, nonsteroidal anti-inflammatory drugs: increased risk of bleeding

Live-virus vaccines: decreased antibody response to vaccine

Myelosuppressants: increased bone marrow depression

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin, creatinine: increased levels

Hemoglobin, neutrophils, platelets, white blood cells: decreased levels

Drug-behaviors. Alcohol use: increased risk of bleeding

Patient monitoring

Monitor I.V. site frequently to avoid extravasation.

• Monitor CBC, blood chemistry, and kidney and liver function tests before each treatment cycle.

Watch closely for blood dyscrasias, hemolytic uremic syndrome, serious pulmonary problems, and anaphylaxis.

• Conduct complete neurologic exam before and after each dose.

• Monitor vital signs and ECG. Evaluate cardiovascular and respiratory status closely.

• Assess patient's comfort level. Keep him warm during infusion to minimize neurologic effects.

• Watch for signs and symptoms of toxicity (paresthesia, nausea, vomiting).

Patient teaching

• Inform patient that chemotherapy drugs can cause many adverse effects.

• Tell patient he'll receive drug from trained health care professionals in hospital setting.

Instruct patient to inform nurse immediately if drug contacts his skin, eyes, or mouth.

• Advise patient to notify nurse if pain or redness occurs at I.V. site.

• Instruct patient to stay warm and avoid iced drinks to minimize neurologic symptoms.

Tell patient to report itching, hives, swelling of hands or face, chest tightness, difficulty breathing, unsteadiness, severe diarrhea or vomiting, or tingling sensation in hands, arms, legs, or feet.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


A platinum-containing chemotherapeutic drug used in the treatment of colorectal cancer.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


Eloxatin® Oncology A parenteral platinum used with 5-FU and leukovorin for advanced colorectal CA. See Cisplatin, 5-FU, Leukovorin.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
The probable mechanism is the direct cytotoxic effect on the eccrine glands of folinic acid, fluorouracil, and oxaliplatin, but more observations are needed to confirm this hypothesis.
This may indicate that oxaliplatin toxic process during the first three months of treatment would not be sufficient to induce impairment of sweat gland function although all patients experiment clinical neuropathy, according to the NCI-CTCAE.
Oxaliplatin treatment in cynomolgus macaques leads to a significant hypersensitivity to 10[degrees]C cold, beginning three days after intravenous oxaliplatin infusion (two-hour i.v.
Initially, CCa cells were incubated with 4 [micro]M of oxaliplatin. When cells recovered to normal growth after a ~48 h incubation, cells were subcultured and continuingly treated with increased concentrations of oxaliplatin (1 [micro]M higher for each subculture).
Neurotoxicity is the major dose-limiting adverse event associated with oxaliplatin. Neurotoxicity is predominantly of sensory peripheral neuropathy and it occurs in about 85-95% of patients.
The present case was strongly suspected to be therapy-related leukemia as he was treated with S-1 plus oxaliplatin for gastric cancer.
The nature of the axial ligand had only a minor influence on the [sup.1]H and [sup.13]C resonances in the oxaliplatin moiety [25, 36].
Oxaliplatin presented [IC.sub.50] values ranging from 0.1 to 5.9 [micro]M for cancer cell lines B16-F10 and MCF7, respectively.
Administration of JHGWD during oxaliplatin chemotherapy significantly reduced the intensity of CIPN symptoms, as well as their duration [30].
Each cell line was treated with different concentrations of Cisplatin, Carboplatin, and Oxaliplatin and their effects were detected at different timing.
Six cycles of neoadjuvant chemotherapy with trastuzumab, oxaliplatin, and fluorouracil were administered from February 2015 to August 2015.
Oxaliplatin [(trans-1)1,2-diaminocyclohexaneoxalate-platinum (II)] is a platinum based chemotherapeutic agent used against metastatics colorectal cancer [6,7].